Human anti-human tigit antibody and its application

An antibody and single-chain antibody technology, applied in the field of biomedicine, can solve the problems of limited benefited patients, poor tumor effect, and unclear reasons, and achieve the effect of enhancing killing activity, superior killing activity, and promoting killing activity.
CN112679610BActive Publication Date: 2021-11-16ACADEMY OF MILITARY MEDICAL SCI
6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
ACADEMY OF MILITARY MEDICAL SCI
Publication Date
2021-11-16

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a human anti-human TIGIT antibody and its application. The anti-human TIGIT antibody disclosed by the present invention contains a heavy chain variable region V H and light chain variable region V L , V H and V L Both consist of determinant complementary regions and framework regions; V H and V L The determinant complementary regions are composed of CDR1, CDR2 and CDR3; V H The amino acid sequences of CDR1, CDR2 and CDR3 are shown in the 30-35th, 50-66th and 99-107th amino acids of SEQ ID No.10; V L The amino acid sequences of CDR1, CDR2 and CDR3 are shown in amino acids 23-33, 49-55 and 88-96 of SEQ ID No.9. The antibody of the invention can bind TIGIT with high affinity, can effectively block the combination of CD155 and TIGIT, and has anti-tumor activity.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the human anti-human TIGIT antibody and its application in the field of biomedicine. Background technique

[0002] Cancer immunotherapy (Cancer Immunotherapy) is a frontier hot field in the basic and clinical research of tumor treatment in recent years. In 2011, the CTLA-4 inhibitor Ipilimumab (Ipilimumab, also known as "Y drug") was approved for marketing. The antibody exerts an anti-tumor effect by activating the immune response mediated by T cells; A whole new era of immunotherapy. Since 2014, PD-1 / PD-L1 antibodies such as Nivolumab (also known as "O drug") and Pembrolizumab (also known as "K drug") have been released one after another. It has achieved remarkable curative effect and profoundly changed the paradigm of cancer treatment. James Allison, an American scientist who promotes the development of CTLA-4 drugs, and Tasuku Honjo, a Japanese scientist who discovered PD-1 / PD-L1 molecules, also won the 2018 Nobel Prize f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More